(4-NH2)-Exatecan CAS:2495742-21-5 is a potent and innovative derivative of Exatecan, a topoisomerase I inhibitor, characterized by the addition of an amino (NH2) functional group at the 4th position of the parent molecule. This modification enhances its pharmacokinetic properties and effectiveness, making it a promising candidate for further investigation in the field of cancer therapy.
Introduction to the application:
In pharmaceutical research and development, (4-NH2)-Exatecan has garnered significant interest for its potential application in targeted cancer treatment. Its unique ability to selectively inhibit topoisomerase I—an enzyme critical for DNA replication—allows for the disruption of cancer cell proliferation, minimizing off-target effects and providing a safer therapeutic option. Ongoing studies on this novel compound are expected to yield valuable insights into its efficacy and expand the therapeutic arsenal against various malignancies.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
